



NEWS RELEASE

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

2026-07-23

JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update.

Conference Call and Webcast Information

Date:	Thursday, August 6, 2026
Time:	8:30 a.m. Eastern time
Conference Call:	United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in Numbers Meeting ID: 780702347
Webcast:	Live and replay webcasts of the call are available here .

About Ligand

Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than

200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand's royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on [X](#) and [LinkedIn](#).

Contacts

Investors:

Melanie Herman

[**investors@ligand.com**](mailto:investors@ligand.com)

(858) 550-7761

Media:

Kellie Walsh

[**media@ligand.com**](mailto:media@ligand.com)

(914) 315-6072

Source: Ligand Pharmaceuticals